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Abstract
Background: Colorectal cancer (CRC) is one of the most common malignancies but the current therapeutic approaches for
advanced CRC are less efficient. Thus, novel therapeutic approaches are badly needed. The purpose of this study is to
investigate the involvement of nuclear protein kinase CK2 a subunit (CK2a) in tumor progression, and in the prognosis of
human CRC.
Methodology/Principal Findings: Expression levels of nuclear CK2a were analyzed in 245 colorectal tissues from patients
with CRC by immunohistochemistry, quantitative real-time PCR and Western blot. We correlated the expression levels with
clinicopathologic parameters and prognosis in human CRC patients. Overexpression of nuclear CK2a was significantly
correlated with depth of invasion, nodal status, American Joint Committee on Cancer (AJCC) staging, degree of
differentiation, and perineural invasion. Patients with high expression levels of nuclear CK2a had a significantly poorer
overall survival rate compared with patients with low expression levels of nuclear CK2a. In multi-variate Cox regression
analysis, overexpression of nuclear CK2a was proven to be an independent prognostic marker for CRC. In addition, DLD-1
human colon cancer cells were employed as a cellular model to study the role of CK2a on cell growth, and the expression of
CK2a in DLD-1 cells was inhibited by using siRNA technology. The data indicated that CK2a-specific siRNA treatment
resulted in growth inhibition.
Conclusions/Significance: Taken together, overexpression of nuclear CK2a can be a useful marker for predicting the
outcome of patients with CRC.
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Introduction
Colorectal cancer (CRC) accounted for about 1 million new
cases in 2002 (9.4% of the world total), and unlike most sites,
numbers were not so different in men and women (ratio, 1.2:1) [1].
In terms of incidence, CRC ranks fourth in frequency in men and
third in women. There is at least a 25-fold variation in occurrence
of CRC worldwide. The highest incidence rates are in North
America, Western Europe, and, in men especially, Japan.
Incidence tends to be low in Africa and intermediate in southern
parts of South America. In Taiwan, CRC ranks as the second most
frequently diagnosed malignancy and causes more than 10000
deaths annually (http://www.doh.gov.tw/statistic/index.htm; ac-
cessed in December 2008). In spite of the current surgical
techniques and chemotherapy that have made significant
improvements, the cure rate for advanced CRC remains low
and the morbidity remains high [2]. Thus, advances in treatment
of this disease are likely to come from a fuller understanding of its
pathogenesis and biological features.
Prognosis of newly diagnosed CRC predominantly relies on the
American Joint Committee on Cancer (AJCC) stage determined
by the depth of invasion, the involvement of the lymph nodes, and
distant metastasis [3,4]. However, in fact, it is well known that
patients with the same AJCC stage CRC display survival
heterogeneity, with some patients exhibiting relatively short
survival times. Accordingly, the identification of more promising
prognostic factors that are indeed highly predictive of CRC
patients undergoing surgical treatment is mandatory. Many studies
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development and progression of CRC [5,6]. Molecular pathology
may be helpful not only to understand the disease pathogenesis,
but also to give useful prognostic molecular markers. Some
suggested biological prognostic factors include overexpression of
vascular endothelial growth factor (VEGF), enhancer of zeste
homologue 2 and transglutaminase 2 [7–9].
Protein kinase CK2 (formerly known as casein kinase 2) is a
highly conserved serine/threonine kinase. It is distributed
ubiquitously in eukaryotic organisms, where it most often appears
to exist in tetrameric complexes consisting of two catalytic subunits
(aa, a’ a’o raa’) and two regulatory b subunits [10,11]. CK2 is a
remarkably multifunctional protein kinase with a vast array of
more than 300 substrates, many of which are critically involved in
the process of cell growth, proliferation, and differentiation
[12,13]. Disruption of Saccharomyces cerevisiae genes encoding both
CK2 catalytic subunits leads to a failure in development, and the
demonstration that knockout of the gene encoding the regulatory
CK2 b subunit in mice is also lethal reinforces the importance of
CK2 in the maintenance of cell viability in normal cell life and
during embryogenesis [14,15]. In the b subunit, certain cysteine
residues may play a role in anchoring the kinase to nuclear
structures. CK2 activity may have a role in cell growth through its
signaling to key sites in nuclear matrix and chromatin structures
[16]. Several growth stimuli can enhance CK2 nuclear shuttling,
so that higher nuclear localization is observed in tumor cells
compared with normal cells [17,18].
Moreover, CK2 dysregulation in tumor cells may influence the
apoptotic activity and to enhance cell survival [19]. CK2 can exert
antiapoptotic effects through various mechanisms. For instance,
CK2 counteract apoptosis by protecting Bid from tumor necrosis
factor–related apoptosis-inducing ligand (TRAIL)–induced cas-
pase-8–mediated degradation [20]. CK2 is also involved in the
phosphorylation of several proteins related to apoptosis, including
p53and nuclear factor-kB [21,22]. In addition, Fas receptor–
mediated cell death is regulated by CK2 expression [23].
The level of CK2 seems to be tightly regulated in normal cells,
resisting a change in their intrinsic level of CK2 [24]. Increasing
evidence indicates that CK2 enzyme is a component of regulatory
protein kinase networks that are involved in several aspects of
cellular transformation and cancer [25]. Increases in CK2 level
and activity have consistently been observed in a variety of human
cancers, including mammary gland, head and neck, and kidney
cancer [26–28]. Overexpression and prognostic significance of
CK2 a subunit have only been observed in lung cancer, prostate
cancer and leukemia [29–31]. To our knowledge, the expression
and prognostic significance of nuclear CK2a in human CRC is
still unknown. The aims of this study were to investigate the
relationship between nuclear CK2a expression and clinicopatho-
logic parameters and prognosis in human CRC patients. We also
evaluated the effects of siRNA-inhibited CK2a expression on the
proliferation of colon cancer cells.
Results
Basic data
Two hundreds and forty-five CRC patients, 139 males and 106
females, were enrolled in this study. Age ranged from 21 to 88
years olds at first diagnosis (mean 64 years). Based on the AJCC
classification, there were 36 stage I patients, 98 stage II patients,
110 stage III patients, and 1 stage IV patient. Follow-up for those
patients ranged from 2.93 to 123.97 months (mean 68.3 months).
During follow-up, 69 patients died of CRC. Postoperative compli-
cations did not occur in these patients.
Nuclear CK2a expression was upregulated and
associated with several clinicopathologic parameters in
CRC
We investigated the expression of nuclear CK2a in 245 CRC
patients by immunohistochemistry, and in four patients by
Western blot. The results indicated that nuclear CK2a expression
was higher in tumor tissues than in non-tumor tissues (Figure 1).
Additionally, quantitative real-time PCR analysis demonstrated
that the expression of CK2a was substantially increased in tumor
tissues when compared with non-tumor tissues (Table 1). As shown
in Table 2, nuclear CK2a expression had a statistically significant
correlation with depth of invasion (P=0.008), nodal status
(P,0.001), AJCC staging (P,0.001), degree of differentiation
(P=0.011), and perineural invasion (P=0.041). The representa-
tive photomicrographs of nuclear CK2a expressions for different
parameters were shown in Figure 2. There was no significant
association between nuclear CK2a expression and age, gender,
and vascular invasion.
Overexpression of nuclear CK2a as an independent
prognostic marker for CRC
Correlations of clinical outcomes with nuclear CK2a expression
are shown in Figure 3. Inferior overall survival was significantly
associated with overexpression of nuclear CK2a (mean labeling
Figure 1. Expression of nuclear CK2a in colorectal tissues.
Nuclear CK2a expression in non-tumor and tumor tissues, analyzed by
immunohistochemistry, was shown in Panel A and B, respectively.
Magnification: 4006. Panel C. Nuclear CK2a expression in four non-
tumor/tumor pairs was examined by Western blot.
doi:10.1371/journal.pone.0017193.g001
Protein Kinase CK2a in Colorectal Cancer
PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e17193index .40%, P,0.0001). Patients with high expression levels of
nuclear CK2a had a ten-year overall survival rate of 22.2%
compared with 72.5% for patients with low expression levels of
nuclear CK2a.
The uni-variate analysis of prognostic markers of CRC is
summarized in Table 3. Nodal status (P=0.025) and overexpres-
sion of nuclear CK2a (P,0.0001) was correlated significantly with
overall survival.
This association between overexpression of nuclear CK2a and
survival remained even after controlling for other well-known
prognostic markers in multi-variate analysis (Table 4). In multi-
variate analysis, overexpression of nuclear CK2a was prognos-
tically independent (hazard ratio =4.53, 95% confidence Interval
=2.46 to 8.32, P,0.0001).
Effect of knock down of CK2a on colon cancer cell
proliferation
To determine the effect of CK2a expression on DLD-1 human
colon cancer cell proliferation, CK2a gene was knocked down by
transfection of CK2a-specific siRNA. Scrambled siRNAs were
used as controls. After CK2a-specific siRNA treatment, the
expression level of nuclear CK2a in DLD-1 cells was significantly
inhibited (Figure 4A). However, scrambled siRNA resulted in no
significant inhibition (Figure 4A). We counted the number of
colonies of siRNA-treated and un-treated DLD-1 cells. The
colonies of CK2a-specific siRNA-treated cells were significantly
fewer than those of un-treated and scrambled siRNA-treated cells
(decreased to 33% (day 8) and 57% (day 14) of those of un-treated
cells, respectively) (Figure 4B). The representative photomicro-
graphs were shown in Figure 4C. The results indicated a role
played by CK2a in promoting cell proliferation and is consistent
with the clinical data described above.
Discussion
Elevated CK2a mRNA level has been reported in several
human cancers, including melanoma and lung cancer [32,33].
However, despite these studies, clinical data dealing with the
specific expression of CK2a at the protein level are scarce. One
recent study showed elevated CK2a protein expression in prostate
cancer [30]. To our knowledge, this is the only study using
immunohistochemistry for evaluating CK2a expression in human
cancers. The expression of nuclear CK2a in human CRC is still
unknown. In the present study, the expression levels of nuclear
CK2a in colorectal tissues from 245 patients with CRC were
assessed, and the results showed that nuclear CK2a expression was
Table 1. Quantification of CK2a mRNA expression by
quantitative real-time PCR in 10 tumor and non-tumor pairs of
colorectal tissues.
Non-tumor Tumor
No. CK2ab -actin DCnon-tumor CK2ab -actin DCtumor
S0059 33.14 23.37 9.77 32.94 25.01 7.93
S0423 29.67 19.64 10.03 29.01 21.17 7.84
S0475 34.06 22.02 12.04 29.43 19.89 9.54
S0480 35.50 21.35 14.15 31.52 22.03 9.49
S0485 35.68 21.49 14.19 32.87 23.02 9.85
S0597 39.23 24.28 14.95 32.10 19.75 12.35
S0641 30.88 20.29 10.59 32.33 22.45 9.88
S0680 31.95 20.17 11.78 30.94 21.56 9.38
S0706 34.30 21.89 12.41 29.46 20.11 9.35
S0708 30.09 20.93 9.16 33.31 26.04 7.27
doi:10.1371/journal.pone.0017193.t001
Table 2. Nuclear CK2a expression in CRC and its correlation with clinicopathologic parameters.
Mean nuclear CK2a labeling index
Parameters n mean SD P*
Age ,65y 107 43.32 29.39 0.704
$65y 138 44.75 28.94
Gender Male 139 43.24 28.80 0.588
Female 106 45.28 29.55
Depth of invasion T1+T2 52 34.62 28.14 0.008
T3+T4 193 46.68 28.88
Nodal status N0 134 34.03 22.28 ,0.001
N1+N2+N3 111 56.31 31.66
Staging I 36 24.44 19.38 ,0.001
II+III+IV 209 47.51 29.17
Differentiation Poor to moderate 223 45.38 29.42 0.011
Well 22 31.36 22.21
Vascular invasion Absence 196 43.06 29.09 0.256
Presence 49 48.37 28.97
Perineural invasion Absence 214 42.69 29.06 0.041
Presence 31 54.03 27.73
*All statistical tests were two-sided. Significance level: P,0.05.
doi:10.1371/journal.pone.0017193.t002
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tissues.
In addition, our data showed CK2a nuclear accumulation in
CRC, consistent with previous study conducted in prostate cancer.
The mechanistic basis of CK2a nuclear accumulation is currently
unclear but, as a CK2 catalytic subunit, its continuous presence in
the nucleus might not only be related to the increased proliferative
capacity of dedifferentiated tumour cells but also to their marked
resistance to apoptotic signals. What could be the functional
consequence of nuclear accumulation of CK2 in cancer cells? One
study performed by Scaglioni et al. demonstrated that CK2
phosphorylated the promyelocytic leukemia protein (PML, a
tumor suppressor) and targeted it for degradation by the
proteasome [34]. Loss of the critical CK2 phosphorylation site
in PML resulted in stabilization of this protein, enhancement of
PML-induced apoptosis. Moreover, in human non-small cell lung
cancers, there is an inverse relationship between PML expression
and CK2 activity. Since PML is a nuclear-matrix-associated
Figure 3. Overall survival analysis of 245 CRC patients
stratified by nuclear CK2a immunoreactivity (low nuclear
CK2a: mean labeling index #40%; high nuclear CK2a: mean
labeling index .40%). All statistical tests were two-sided. Signifi-
cance level: P,0.05.
doi:10.1371/journal.pone.0017193.g003
Table 3. Uni-variate analysis of prognostic markers in 245
patients with CRC.
Variables HR 95% CI P*
Depth of invasion T1+T2 1
T3+T4 0.86 0.49–1.50 0.591
Nodal status N0 1
N1+N2+N3 1.74 1.07–2.83 0.025
Staging I 1





Vascular invasion Absence 1
Presence 1.19 0.68–2.09 0.538
Perineural invasion Absence 1




.40 4.53 2.55–8.03 ,0.0001
*All statistical tests were two-sided. Significance level: P,0.05. HR = hazard
ratio; CI = confidence interval.
doi:10.1371/journal.pone.0017193.t003
Figure 2. The representative IHC nuclear CK2a staining
corresponding to mean nuclear CK2a labeling index values
for different parameters. Magnification: 4006.
doi:10.1371/journal.pone.0017193.g002
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relevant to inactivate the tumor-suppressive functions of PML. In
another study, CK2 has been recently described as a key regulator
of the tumor suppressor NKX3.1 in LNCaP prostate cancer cells.
Like PML, it was found that blocking CK2 activity in LNCaP cells
with inhibitor apigenin led to a rapid decrease in NKX3.1
accumulation that was rescued by proteasome inhibition [35].
In the current study, we demonstrated for the first time that
overexpression of nuclear CK2a in CRC tissues was closely
correlated with several clinicopathologic parameters including the
depth of tumor invasion, lymph node metastasis, and perineural
invasion. Although the mechanisms underlying these associations
are still unclear, several lines of evidence for these correlations will
be discussed in below. Firstly, the evidence for the association
between overexpression of nuclear CK2 and the depth of invasion
Table 4. Multi-variate analysis of prognostic markers in 245
patients with CRC.
Variables HR 95% CI P*
Nodal status N0 1




.40 4.53 2.46–8.32 ,0.0001
*All statistical tests were two-sided. Significance level: P,0.05.
doi:10.1371/journal.pone.0017193.t004
Figure 4. Effect of CK2a gene silencing on colon cancer cell proliferation. Panel A. Nuclear CK2a expression in siRNA treated and un-treated
DLD-1 colon cancer cells was examined by Western blot analysis. Panel B. Histograms representing the cell proliferation assay results based on
the average of three independent experiments. *denotes P,0.001 compared with un-treated DLD-1 cells. Panel C. The representative
photomicrographs.
doi:10.1371/journal.pone.0017193.g004
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been associated with cancer-cell invasion and metastasis [36]. A
recent study showed that PC-3 human prostate cancer cells over-
expressing membrane type-1 matrix metalloproteinase (MT1-
MMP) grew faster than mock-transfected control cells [37]. This
result suggested that invasion-promoting MT1-MMP is directly
linked to tumor aggressiveness. Genome-wide expression profiling
of MT1-MMP-overexpressing versus MT1-MMP-silenced cancer
cells and a further data mining analysis of the preexisting
expression database of 190 human tumors of 14 cancer types led
to identify 11 genes, including CK2, the expression of which
correlated firmly and universally with that of MT1-MMP [38].
Secondly, by using immunohistochemistry, the association be-
tween VEGF-C and the development of lymph node metastasis
has been described by Yonemura Y et al [39]. In response to
hypoxia, happened in most tumors grown larger than 1 mm
3, the
expression of VEGF-C can be stimulated by hypoxia-inducible
factor-1 (HIF-1) [40]. It was shown that inhibitors of CK2 blocked
the activation of HIF-1, and then the expression of VEGF-C [41].
Finally, the increased neurite formation demonstrated in the
previous in vitro studies suggests that axonal migration may be a
key element of perineural invasion. Axonal growth is a complex
process that requires neurotrophic growth factors and axonal
guidance molecules [42,43]. One study performed by Arevalo et
al. showed that nerve growth factor, one of the neurotrophic
growth factors, can stimulate axon growth through activation of
CK2 [44].
Our study demonstrated that overexpression of nuclear CK2a
can be an independent prognostic marker for CRC. Clinical data
dealing with the prognostic value of CK2a are limited. Using
global gene expression profiling, the CK2a gene has been
identified as a prognostic marker in patients with squamous cell
carcinoma of the lung [29]. Laramas et al. provided the evidence
for a strong association between a nuclear localization of CK2a
and poor prognostic factors in human prostate cancer [30]. In
addition, studies of Kim et al. showed that overexpression of
CK2a protein in leukemia was associated with poor patient
outcome [31]. To our knowledge, there is no report mentioning
the prognostic significance of nuclear CK2a in human CRC. It
is noteworthy to observe that, for the first time, overexpression
of nuclear CK2a can be an independent prognostic marker
for CRC. Overexpression of nuclear CK2a is hence a useful
marker for predicting the outcome of patients with CRC who
had a surgical resection of the tumor. The patients with CRC




The patient cohort comprised 245 consecutive CRC cases from
1998 through 2002 documenting pathologic and clinical factors
and clinical outcome. None of these patients had received
preoperative chemotherapy and/or radiotherapy. The non-tumor
part was taken from the grossly normal colorectal mucosa away
from the tumor in resected colorectal specimen. Clinicopathologic
parameters of CRCs were determined according to the AJCC
classification. The follow-up duration was defined as the period
between the operation date and day of the last visit, according to
the patient’s chart. The institutional review board at Chi-Mei
Medical Center approved the tissue acquisition protocol to
conduct this study. Written informed consent was obtained from
each participant before tissue acquisition. Tumor/non-tumor pairs
of colorectal tissues were analyzed for nuclear CK2a expression.
Immunohistochemical analysis
Nuclear CK2a expression was analyzed by immunohistochem-
istry. Paraffin-embedded tissue blocks were sectioned at 5 mm and
transferred to microscope slides (Muto Pure Chemicals, Tokyo,
Japan). Hepatoma was used a positive control for CK2a. The
negative control consisted of the omission of the primary antibody
and incubation with phosphate buffer saline. After rehyfration and
antigen retrieval, antigen blocking was performed using Dako
REAL Peroxidase-Blocking Solution (Dako, Carpinteria, CA) for 5
minutes. The slides were subsequently incubated with a primary
antibody: polyclonal anti-CK2a (Stressgen Bioreagents, Victoria,
Canada) for 30 minutes at room temperature at a dilution of 1:50.
Detection of the immunoreactive staining was carried out by the
avidin-biotin-peroxidase complex method according to the
manufacturer’s instructions. A sensitive Dako REAL EnVision
Detection System (Dako) was used as the detection system. After
incubation with diaminobenzidine for 5-8 minutes, the sections
were counterstained and mounted for microscopic interpretation.
The immunoreactivity was independently scored by two pathol-
ogists (C-F Li and C-L Fang). The percentage of tumor cells with
moderate or strong nuclear immunoreactivity was recorded, and
scores from the same patient were averaged to obtain a mean
nuclear CK2a labeling index. The cutoff of the mean labeling
index to define nuclear CK2a overexpression was nuclear
reactivity in .40% cells (median value). Clinical data collection
and immunohistochemical analysis were performed independently
of each other, in an investigator-blinded study.
RNA extraction and cDNA synthesis
According to the manufacturer’s instructions, total RNA from
10 tumor and non-tumor pairs of colorectal tissues was isolated by
using an RNA extraction kit (Sigma, St. Louis, MO). RNA quality
was analyzed by using Agilant 2100 Bioanalyzer. The RIN values
of all 20 samples were above 7. cDNA synthesis was performed as
described in our previous study [45]. Synthesized cDNA was
stored at 220uC until use.
Primers and probes
Taqman Gene Expression Assays including primers and probes
of CK2a and b-actin, an internal control, were purchased from
Applied Biosystems. The Assay numbers of CK2a and b-actin
were Hs00751002_s1, and Hs99999903_m1, respectively.
Quantitative real-time PCR
The expression levels of the target genes were measured using
quantitative real-time PCR in the ABI Prism 7300 Sequence
Detection System (Applied Biosystems) as described in our previous
study [45]. Threshold cycle (Ct) is the fractional cycle number at
whichthefluorescence generatedbycleavage of the probeexceedsa
fixed level above baseline. For a chosen threshold, a smaller starting
copy number results in a higher Ct value. The amount of CK2a
mRNA in tumor or non-tumor tissues, standardized against the
amount of b-actin mRNA, was expressed as DCtumor or DCnon-tumor =
Ct (CK2a) - Ct (b-actin).
Cell culture and siRNA treatment
Human colon cancer cell line (DLD-1) was obtained from the
Food Industry Research and Development Institute (Hsinchu,
Taiwan). Cells were cultured in RPMI-1640 supplemented with
10% heat-inactivated fetal bovine serum (Moregate BioTech,
Bulimba QLD, Australia), 100 units/ml penicillin G, 100 mg/ml
streptomycin sulfate, and 250 ng/ml amphotericin B (all from
Sigma). Cells were grown at 37uC in a humidified atmosphere
Protein Kinase CK2a in Colorectal Cancer
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with 30 nM CK2a-specific or scrambled siRNA (Applied
Biosystems), using siPORT NeoFX Transfection Agent. 48 hours
post-transfection, nuclear proteins were extracted, and then
Western blot was performed to evaluate the effect of siRNA
treatment.
Nuclear protein preparation
Total cellular and tissue nuclear proteins were extracted with
NE-PER Nuclear and Cytoplasmic Extraction Reagents (Pierce
Biotechnology, Rockford, IL), according to the instructions of the
manufacturer. The samples were stored at 280uC until used. The
protein concentration was determined using a BCA Protein
Assay Kit (Pierce Biotechnology) with bovine serum albumin as a
standard.
Immunoblotting
Denatured protein samples were subjected to 10% SDS-PAGE.
Proteins were transferred to nitrocellulose membranes. Blocked
blots were incubated at room temperature overnight with anti-
CK2a polyclonal antibody (1:161 dilution). b-actin (Sigma, 1:8000
dilution) was used as an internal control for equal protein loading.
Blots were further incubated with secondary antibodies conjugated
with peroxidase (Sigma) for 1 hour at room temperature.
Enhanced chemiluminescence reagents (Pierce Biotechnology)
were used to visualize the targeted proteins, which were then
semi-quantitatively measured by densitometry. All the experiments
were conducted three times, independently.
Cell proliferation assay
After siRNA treatment, the transfected cells were cultured in a
37uC, 5% CO2 incubator for 4, 8 and 14 days. Individual colonies
(.50 cells/colony) were fixed, stained using a solution of 1%
crystal violet in methanol for 30 minutes, and counted. The assay
was conducted three times, independently. For each experiment,
two wells per condition were used. Error bars are S. D.
Statistical analysis
DifferencesinnuclearCK2a expression between tumorand non-
tumor tissues in the same patient and in cell proliferation were
analyzed using a paired t test. Some clinicopathologic parameters
were examined in this study. They were age, gender, depth of
invasion, nodal status, staging, degree of differentiation, vascular
and perineural invasion. The correlation between nuclear CK2a
expression and clinicopathologic parameters was examined with x
2
test. All time-to-event endpoints according to various clinicopath-
ologic parameters were plotted by the Kaplan-Meier method and
the significance was then determined by a uni-variate log-rank test.
In principle, those significant parameters in uni-variate analysis
(P#0.05) were entered into multi-variate Cox regression model to
determine the hazard ratio and independence of prognostic impact
in a stepwise backward fashion. All of the data were analyzed using
the SPSS software version 14 (SPSS, Chicago, IL). A P value of
,0.05 was considered significant.
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